Corcept Therapeutics Incorporated CORT
116.10
(2.41)
(2.03%)
as of 25 Sep
- Market cap
- $12.9B
- P/E
- 223×
Follow CORT
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 8.08% | 7.07% | 14.79% | 16.47% |
+8 more TTM periods Free account |
|
| 6.41% | 5.62% | 11.71% | 13.02% | ||
ROIC |
1.01% | (1.71%) | 9.98% | 19.01% | |
Return on Tangible Assets |
18.63% | 16.67% | 30.56% | 28.22% | |
Average Days of Receivables |
33.79 | 18.54 | 28.66 | 34.29 | |
Free Cash Flow per Share |
1.01 | 1.15 | 1.37 | 1.58 | |
Free Cash Flow |
106.92 | 120.15 | 141.79 | 163.32 | |
Capital Expenditures |
(2.78) | (0.31) | (0.21) | (0.28) | |
Piotroski F-Score |
4.00 | 4.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
10.82% | 12.34% | 13.85% | 15.45% | |
Accounts Receivable Turnover |
11.74 | 15.25 | 13.39 | 11.46 | |
Accounts Payable Turnover |
0.73 | 0.44 | 0.47 | 0.50 | |
Inventory Turnover |
1.11 | 0.99 | 1.03 | 1.31 | |
Average Days of Payables |
386.38 | 903.37 | 1,137.56 | 939.11 | |
Days of Inventory on Hand |
341.68 | 349.62 | 361.93 | 336.67 | |
Tax Rate |
1.09 | 2.90 | 0.50 | 0.20 | |
Research and Development Expense of Revenue |
30.56% | 33.86% | 33.48% | 35.13% | |
Selling, General and Administrative Expense of Revenue |
66.98% | 65.46% | 58.93% | 54.22% | |
Share Based Compensation of Revenue |
11.57% | 11.14% | 11.10% | 10.86% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.02 | 2.58 | 1.45 | 1.56 | |
Depreciation/Fixed assets |
(0.52) | (0.97) | (1.70) | (4.33) | |
Capex/Depreciation |
1.04 | 0.10 | 0.07 | 0.03 | |
Revenue per Share |
7.88 | 7.36 | 7.33 | 7.16 | |
Operating CF per Share |
1.04 | 1.15 | 1.37 | 1.58 | |
Capex per Share |
(0.03) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
6.53% | 6.07% | 12.89% | 14.12% |
Columns are period end dates